Literature DB >> 22200885

Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line.

Pavel Barta1, Jennie Malmberg, Ludmila Melicharova, John Strandgård, Anna Orlova, Vladimir Tolmachev, Milan Laznicek, Karl Andersson.   

Abstract

Cell lines are common model systems in the development of therapeutic proteins and in the research on cellular functions and dysfunctions. In this field, the protein interaction assay is a frequently used tool for assessing the adequacy of a protein for diagnostic and therapeutic purposes. In this study, we investigated the extent to which the interaction characteristics depend on the choice of cell line for HER-family receptors. The interaction characteristics of two therapeutic antibodies (trastuzumab and cetuximab) and one Affibody molecule (ZHER2:342), interacting with the intended receptor were characterized with high precision using an automated real-time interaction method, in different cell lines (HaCaT, A431, HEP-G2, SKOV3, PC3, DU-145). Clear differences in binding affinity and kinetics, up to one order of magnitude, were found for the interaction of the same protein binding to the same receptor on different cells for all three proteins. For HER-family receptors, it is therefore important to refer to the measured affinity for a protein-receptor interaction together with the hosting cell line. The ability to accurately measure affinity and kinetics of a protein-receptor interaction on cell lines of different origins may increase the understanding of underlying receptor biology, and impact the selection of candidates in the development of therapeutic or diagnostic agents.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22200885     DOI: 10.3892/ijo.2011.1307

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  14 in total

1.  Resolving the EGF-EGFR interaction characteristics through a multiple-temperature, multiple-inhibitor, real-time interaction analysis approach.

Authors:  Hanna Björkelund; Lars Gedda; Magnus Malmqvist; Karl Andersson
Journal:  Mol Clin Oncol       Date:  2012-10-30

2.  Impact of assay temperature on antibody binding characteristics in living cells: A case study.

Authors:  João Crispim Encarnação; Pavel Barta; Torgny Fornstedt; Karl Andersson
Journal:  Biomed Rep       Date:  2017-09-14

3.  The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule.

Authors:  Javad Garousi; Ken G Andersson; Johan H Dam; Birgitte B Olsen; Bogdan Mitran; Anna Orlova; Jos Buijs; Stefan Ståhl; John Löfblom; Helge Thisgaard; Vladimir Tolmachev
Journal:  Sci Rep       Date:  2017-07-20       Impact factor: 4.379

4.  Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe.

Authors:  Hadis Honarvar; Enrica Calce; Nunzianna Doti; Emma Langella; Anna Orlova; Jos Buijs; Valentina D'Amato; Roberto Bianco; Michele Saviano; Vladimir Tolmachev; Stefania De Luca
Journal:  Sci Rep       Date:  2018-02-14       Impact factor: 4.379

5.  Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors.

Authors:  Anzhelika Vorobyeva; Olga Bragina; Mohamed Altai; Bogdan Mitran; Anna Orlova; Alexey Shulga; Galina Proshkina; Vladimir Chernov; Vladimir Tolmachev; Sergey Deyev
Journal:  Contrast Media Mol Imaging       Date:  2018-06-06       Impact factor: 3.161

6.  Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs.

Authors:  Mohamed Altai; Charles Dahlsson Leitao; Sara S Rinne; Anzhelika Vorobyeva; Christina Atterby; Stefan Ståhl; Vladimir Tolmachev; John Löfblom; Anna Orlova
Journal:  Cells       Date:  2018-10-11       Impact factor: 6.600

7.  PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules.

Authors:  Javad Garousi; Ken G Andersson; Bogdan Mitran; Marie-Louise Pichl; Stefan Ståhl; Anna Orlova; John Löfblom; Vladimir Tolmachev
Journal:  Int J Oncol       Date:  2016-02-02       Impact factor: 5.650

8.  Cyclic versus Noncyclic Chelating Scaffold for 89Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression.

Authors:  Dominik Summer; Javad Garousi; Maryam Oroujeni; Bogdan Mitran; Ken G Andersson; Anzhelika Vorobyeva; John Löfblom; Anna Orlova; Vladimir Tolmachev; Clemens Decristoforo
Journal:  Mol Pharm       Date:  2017-12-01       Impact factor: 4.939

9.  Relationship between the agonist activity of synthetic ligands of TRAIL-R2 and their cell surface binding modes.

Authors:  Neila Chekkat; Caterina M Lombardo; Cendrine Seguin; Marie-Charlotte Lechner; Florent Dufour; Yves Nominé; Marcella De Giorgi; Benoit Frisch; Olivier Micheau; Gilles Guichard; Danièle Altschuh; Sylvie Fournel
Journal:  Oncotarget       Date:  2018-02-17

10.  Influence of composition of cysteine-containing peptide-based chelators on biodistribution of 99mTc-labeled anti-EGFR affibody molecules.

Authors:  Maryam Oroujeni; Ken G Andersson; Xenia Steinhardt; Mohamed Altai; Anna Orlova; Bogdan Mitran; Anzhelika Vorobyeva; Javad Garousi; Vladimir Tolmachev; John Löfblom
Journal:  Amino Acids       Date:  2018-05-04       Impact factor: 3.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.